ZA200809874B - Method of inhibiting c kit kinase - Google Patents

Method of inhibiting c kit kinase

Info

Publication number
ZA200809874B
ZA200809874B ZA2008/09874A ZA200809874A ZA200809874B ZA 200809874 B ZA200809874 B ZA 200809874B ZA 2008/09874 A ZA2008/09874 A ZA 2008/09874A ZA 200809874 A ZA200809874 A ZA 200809874A ZA 200809874 B ZA200809874 B ZA 200809874B
Authority
ZA
South Africa
Prior art keywords
inhibiting
kit kinase
kinase
kit
Prior art date
Application number
ZA2008/09874A
Other languages
English (en)
Inventor
Carl R Illig
Shelley K Ballentine
Jinsheng Chen
Sanath K Meegalla
Mark J Wall
Kenneth Wilson
M Jonathan Rudolph
Renee Louise Desjarlais
Christopher J Molloy
Carl L Manthey
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ZA200809874B publication Critical patent/ZA200809874B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2008/09874A 2006-04-20 2008-11-19 Method of inhibiting c kit kinase ZA200809874B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79347106P 2006-04-20 2006-04-20
PCT/US2007/066985 WO2007124369A2 (en) 2006-04-20 2007-04-19 Method of inhibiting c kit kinase

Publications (1)

Publication Number Publication Date
ZA200809874B true ZA200809874B (en) 2010-02-24

Family

ID=38625740

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2008/09874A ZA200809874B (en) 2006-04-20 2008-11-19 Method of inhibiting c kit kinase

Country Status (21)

Country Link
EP (2) EP2397138B1 (enExample)
JP (1) JP5595727B2 (enExample)
KR (1) KR101448052B1 (enExample)
CN (2) CN102670605B (enExample)
AU (1) AU2007240400B2 (enExample)
BR (1) BRPI0710542B8 (enExample)
CA (1) CA2649755C (enExample)
CO (1) CO6382175A2 (enExample)
CR (1) CR10450A (enExample)
EA (1) EA016611B1 (enExample)
EC (1) ECSP088842A (enExample)
ES (2) ES2458291T3 (enExample)
GT (1) GT200800225A (enExample)
IL (1) IL194846A (enExample)
MX (1) MX2008013528A (enExample)
MY (1) MY147226A (enExample)
NO (1) NO342001B1 (enExample)
NZ (1) NZ572200A (enExample)
SG (1) SG171592A1 (enExample)
WO (1) WO2007124369A2 (enExample)
ZA (1) ZA200809874B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2573831T3 (es) 2011-07-27 2016-06-10 Ab Science Derivados de oxazol y tiazol como inhibidores selectivos de la proteína quinasa (C-kit)
CN104370880A (zh) * 2013-01-24 2015-02-25 韩冰 一类蛋白酶抑制剂及其制备方法和用途
TR201807959T4 (tr) 2013-07-22 2018-06-21 Idorsia Pharmaceuticals Ltd 1-(Piperazın-1-il)-2- ([1,2,4] triazol-1-il)-etanon türevleri.
AR103399A1 (es) 2015-01-15 2017-05-10 Actelion Pharmaceuticals Ltd Derivados de (r)-2-metil-piperazina como moduladores del receptor cxcr3
RS58349B1 (sr) 2015-01-15 2019-03-29 Idorsia Pharmaceuticals Ltd Hidroksialkil-piperazinski derivati kao modulatori cxcr3 receptora
CN105753770A (zh) * 2015-05-27 2016-07-13 上海佐林生物医药有限公司 蛋白激酶抑制剂制备方法、中间体、制备方法及应用
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
EP1179541B1 (en) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
ITMI992711A1 (it) * 1999-12-27 2001-06-27 Novartis Ag Composti organici
MXPA05001277A (es) * 2002-08-02 2005-10-06 Ab Science 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit.
ATE465731T1 (de) * 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
GB0326601D0 (en) * 2003-11-14 2003-12-17 Novartis Ag Organic compounds
CN1934107A (zh) * 2004-01-30 2007-03-21 Ab科学公司 作为酪氨酸激酶抑制剂的2－(3－取代芳基)氨基－4－芳基－噻唑
CN101437514B (zh) 2004-10-22 2012-04-25 詹森药业有限公司 C-fms激酶抑制剂
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
AU2006304897B2 (en) * 2005-10-18 2012-07-12 Janssen Pharmaceutica N.V. Method of inhibiting FLT3 kinase
JP2009534380A (ja) * 2006-04-20 2009-09-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ｃ−ｆｍｓキナーゼインヒビター
KR101367645B1 (ko) * 2006-04-20 2014-02-27 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제의 저해제로서의 복소환식 화합물
EP2016070B1 (en) * 2006-04-20 2016-01-13 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase

Also Published As

Publication number Publication date
IL194846A (en) 2015-07-30
JP5595727B2 (ja) 2014-09-24
SG171592A1 (en) 2011-06-29
ECSP088842A (es) 2008-11-27
WO2007124369A2 (en) 2007-11-01
EA200870454A1 (ru) 2009-04-28
EP2397138B1 (en) 2013-12-11
KR20080111545A (ko) 2008-12-23
WO2007124369A3 (en) 2008-03-06
CN102670605A (zh) 2012-09-19
IL194846A0 (en) 2009-08-03
EP2015748A2 (en) 2009-01-21
AU2007240400A1 (en) 2007-11-01
CA2649755A1 (en) 2007-11-01
EP2015748B1 (en) 2012-07-04
NZ572200A (en) 2011-09-30
CN102670605B (zh) 2015-07-29
ES2458291T3 (es) 2014-04-30
CN101610768A (zh) 2009-12-23
CN101610768B (zh) 2012-03-21
NO342001B1 (no) 2018-03-12
EP2397138A1 (en) 2011-12-21
HK1124766A1 (en) 2009-07-24
NO20084892L (no) 2009-01-06
MX2008013528A (es) 2008-10-29
EA016611B1 (ru) 2012-06-29
AU2007240400B2 (en) 2013-08-22
CO6382175A2 (es) 2012-02-15
GT200800225A (es) 2009-05-15
KR101448052B1 (ko) 2014-10-07
MY147226A (en) 2012-11-14
BRPI0710542B1 (pt) 2021-01-12
ES2389678T3 (es) 2012-10-30
BRPI0710542B8 (pt) 2021-05-25
CR10450A (es) 2009-02-23
JP2009534418A (ja) 2009-09-24
CA2649755C (en) 2014-12-02
BRPI0710542A2 (pt) 2012-06-05

Similar Documents

Publication Publication Date Title
IL284889A (en) Imidazotriazines and imidazopyrimidines as kinase inhibitors
IL190727A0 (en) Method of inhibiting flt3 kinase
ZA200900884B (en) Method of scale inhibition
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en) PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
PL2079727T3 (pl) Inhibitory kinazy
ZA200706345B (en) Amino-pyridines as inhibitors of ß-secretase
ZA200901073B (en) Kinase inhibitor
IL194845A0 (en) Inhibitors of c-fms kinase
EP2015745A4 (en) MACROCYCLIC KINASE INHIBITORS
WO2008036459A8 (en) Inhibitors of rho kinase
PT2114951E (pt) Inibidores inovadores da fosfodiesterase
IL194846A0 (en) Method of inhibiting c kit kinase
GB0705854D0 (en) Methods of construction
GB0608823D0 (en) Inhibitors of P13 kinase
GB0608837D0 (en) Inhibitors of MAP kinase
IL197981A0 (en) Kinase inhibitors
GB0603522D0 (en) Kinase inhibition
GB2443299B (en) Method of monodiameter well construction
ZA200810573B (en) Substituted 3-cyanopyridines as protein kinase inhibitors
GB0621205D0 (en) Inhibitors of PLK
GB0621720D0 (en) Inhibitors of ikk- serine-threonine protein kinase
GB0621606D0 (en) Inhibitors of p13 kinase
GB0613968D0 (en) Method of determination
GB0606238D0 (en) Kinase inhibition